Zevra Therapeutics Inc (ZVRA) Stock Price, Quote & News

Company Profile

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug pro...

Industry: Biotechnology

Sector: Healthcare

Phone: 321 939 3416

Website: zevra.com

Address:

1180 Celebration Boulevard, Suite 103, Celebration, United States

EthanStawk Aug. 23 at 6:57 PM

$ZVRA M&A for rare disease companies is what's on every bios mind right now. I do not think there's a more valid prospect in the space right now. I think our management will make it take a dumb fucking deal that benefits them more than shareholders, but I think it will happen.

1 · Reply

Torn891 Aug. 23 at 10:38 AM

$ZVRA I was at a farm today and saw a half Zebra, half Jackass, with limited ability to see clearly. I think I found this boards mascot.

1 · Reply

great_investment_thesis Aug. 23 at 6:01 AM

$ZVRA I’m extremely skeptical of the rumor mill. Don’t buy into any of it. These two rumors could easily stem from the same speculation tree, and the fact they don’t overlap says a lot. Feels like someone’s playing the market, cashing in on volatility. The very fact we’ve seen an insider buy tells you the board knows nothing about any deal. Otherwise, that’s a straight-up breach of fiduciary duty and opens the door to insider trading investigations. Focus on the fundamentals. Mipplyfa: 30M+ per quarter by EOY 89 patients in EU EAP = another 35–40M immediately UK not even in the conversation yet, but a few dozen more patients right after EMA is realistic Lawsuit resolution on September 22 Exclusivity expansion - every additional year lifts the NPV We could easily generate $1 EPS in a year, so do your math.

2 · Reply

Nolettuce Aug. 23 at 5:18 AM

$ZVRA So, smart people, if the BO rumours are true (and it seems like this is viewed negatively). What’s the worst case price? What’s a likely price?

1 · Reply

Kittinvestments Aug. 23 at 4:59 AM

$ZVRA a BO is good, but a BO by a small company no thanks! I don’t want some struggling small pharma’s stock in exchange for zevra’s. I want at least $25/share cash. I rather management continue executing and selling Mypliffa, keeping the cash and having a $1.5B valuation on our own in 2years.

1 · Reply

vinnvegas Aug. 23 at 3:12 AM

$ZVRA someone tell Rod to unblock me please. Several years ago I made an ill advised comment about his mother in jest, for which, I am sorry. The only bear that actually was semi capable of telling the truth. He owes me a beer in Vegas when this buyout happens

2 · Reply

ZVRA100 Aug. 23 at 1:55 AM

$ZVRA thinking about it, double the size could also just mean double the number of employees….. or perhaps a private valuation if talking about market cap, or in a different market like UK…

1 · Reply

KemPharm_rocks Aug. 23 at 12:06 AM

$ZVRA If there is any truth to the rumor, it appears that we have a bit of stay of execution… perhaps time enough for someone to talk some sense into Neil’s head. It would have to be the tutes though, because he ain’t going to listen to us.

2 · Reply

Smedley1 Aug. 22 at 9:55 PM

$ZVRA anyone thrilled at the prospect of $10 cash and $10 TVTX stock as BO….im not…

2 · Reply

Peterson28 Aug. 22 at 8:51 PM

$ZVRA MM is doing the magic to keep the 100% phantom premium. BO price likely falls between 20-25.

3 · Reply

Zevra Therapeutics, Inc. (ZVRA) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 11 days ago

Zevra Reports Second Quarter 2025 Financial Results and Corporate Update

Aug 4, 2025, 7:30 AM EDT - 19 days ago

Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call

Jul 28, 2025, 6:00 AM EDT - 26 days ago

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

Jul 18, 2025, 7:30 AM EDT - 5 weeks ago

Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)

Jul 16, 2025, 7:30 AM EDT - 5 weeks ago

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism

May 29, 2025, 4:35 PM EDT - 3 months ago

Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

May 21, 2025, 7:30 AM EDT - 3 months ago

All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees

May 13, 2025, 10:45 PM EDT - 3 months ago

Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript

May 6, 2025, 7:30 AM EDT - 3 months ago

Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call

Apr 17, 2025, 7:30 AM EDT - 4 months ago

Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism

Apr 7, 2025, 7:30 AM EDT - 4 months ago

Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Mar 31, 2025, 4:12 PM EDT - 5 months ago

Zevra Therapeutics Files Preliminary Proxy

Mar 11, 2025, 8:16 PM EDT - 5 months ago

Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 4:05 PM EDT - 5 months ago

Zevra Reports Full Year 2024 and Fourth Quarter Financial Results

Feb 28, 2025, 7:30 AM EST - 6 months ago

Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,' to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C

Feb 27, 2025, 7:30 AM EST - 6 months ago

Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Feb 26, 2025, 9:46 AM EST - 6 months ago

Zevra to Report 2024 Fourth Quarter and Full Year Financial Results

Feb 24, 2025, 4:02 PM EST - 6 months ago

Zevra to Participate at Upcoming Investor Conferences

Jan 30, 2025, 7:30 AM EST - 7 months ago

Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™

Jan 29, 2025, 4:05 PM EST - 7 months ago

Zevra Therapeutics to Participate at Upcoming Investor Conferences

Jan 8, 2025, 11:13 AM EST - 8 months ago

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

AMGN BBIO BMY IOVA LLY MDGL MRK

Dec 17, 2024, 7:30 AM EST - 8 months ago

Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024

Dec 6, 2024, 5:00 PM EST - 9 months ago

Zevra Therapeutics Announces Organizational Changes

Nov 21, 2024, 4:51 PM EST - 9 months ago

Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C

Nov 13, 2024, 7:12 AM EST - 10 months ago

Zevra Therapeutics, Inc. (ZVRA) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 4:36 PM EST - 10 months ago

Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting

Nov 6, 2024, 7:30 AM EST - 10 months ago

Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13

Oct 31, 2024, 7:30 AM EDT - 10 months ago

Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024

Oct 10, 2024, 7:30 AM EDT - 11 months ago

Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

Sep 24, 2024, 7:30 AM EDT - 11 months ago

Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024

Sep 20, 2024, 12:08 PM EDT - 1 year ago

Zevra Therapeutics' MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C

Sep 20, 2024, 10:14 AM EDT - 1 year ago

US FDA approves Zevra's genetic disorder treatment

Sep 6, 2024, 8:30 AM EDT - 1 year ago

Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

Aug 13, 2024, 9:45 PM EDT - 1 year ago

Zevra Therapeutics, Inc. (ZVRA) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 12:00 AM EDT - 1 year ago

Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Zevra Therapeutics Announces Proposed Public Offering of Common Stock

Aug 7, 2024, 9:34 AM EDT - 1 year ago

Zevra Therapeutics to Present at Canaccord Genuity's 44th Annual Growth Conference

Aug 2, 2024, 5:50 PM EDT - 1 year ago

FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C

Jul 30, 2024, 8:38 AM EDT - 1 year ago

Zevra Therapeutics to Report Second Quarter 2024 Financial Results

Jun 25, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics Expands Executive Leadership Team

Jun 18, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders

Jun 3, 2024, 11:00 AM EDT - 1 year ago

Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting

May 8, 2024, 2:53 PM EDT - 1 year ago

Zevra Therapeutics, Inc. (ZVRA) Q1 2024 Earnings Call Transcript

May 8, 2024, 7:00 AM EDT - 1 year ago

Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

May 1, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024

Apr 29, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics' President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024

Apr 15, 2024, 5:01 PM EDT - 1 year ago

Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting

Apr 10, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility

EthanStawk Aug. 23 at 6:57 PM

1 · Reply

Torn891 Aug. 23 at 10:38 AM

$ZVRA I was at a farm today and saw a half Zebra, half Jackass, with limited ability to see clearly. I think I found this boards mascot.

1 · Reply

great_investment_thesis Aug. 23 at 6:01 AM

2 · Reply

Nolettuce Aug. 23 at 5:18 AM

$ZVRA So, smart people, if the BO rumours are true (and it seems like this is viewed negatively). What’s the worst case price? What’s a likely price?

1 · Reply

Kittinvestments Aug. 23 at 4:59 AM

1 · Reply

vinnvegas Aug. 23 at 3:12 AM

2 · Reply

ZVRA100 Aug. 23 at 1:55 AM

$ZVRA thinking about it, double the size could also just mean double the number of employees….. or perhaps a private valuation if talking about market cap, or in a different market like UK…

1 · Reply

KemPharm_rocks Aug. 23 at 12:06 AM

2 · Reply

Smedley1 Aug. 22 at 9:55 PM

$ZVRA anyone thrilled at the prospect of $10 cash and $10 TVTX stock as BO….im not…

2 · Reply

Peterson28 Aug. 22 at 8:51 PM

$ZVRA MM is doing the magic to keep the 100% phantom premium. BO price likely falls between 20-25.

3 · Reply

BillyTheKid62 Aug. 22 at 8:28 PM

$ZVRA They will printout Knights80 ZVRA s shares so he can be buried with them when he passes . Poor guy doesn't know when to sell .

3 · Reply

ChiefTanto Aug. 22 at 7:58 PM

$ZVRA Will they pin it at the same close as last friday? With 40-50% daily short ratio since last thursday and every move getting sold into - this looks like its got a ceiling around 9.50.

2 · Reply

ZVRA100 Aug. 22 at 6:29 PM

$ZVRA hey bloomberg/benzinga/nasdaq. Where’s your buyout rumor for zevra at?

0 · Reply

Gupulamba Aug. 22 at 5:51 PM

$ZVRA what is the possibility of going up to 13 again

2 · Reply

RaySan Aug. 22 at 4:19 PM

$ZVRA Markets way up. Buy out rumors. and meanwhile ZVRA......

0 · Reply

OldManLogan Aug. 22 at 3:35 PM

$ZVRA Wonderful! Most of us longs hope the latest BO rumor ISN'T true. 🤣

5 · Reply

BMW2002 Aug. 22 at 3:05 PM

$ZVRA

0 · Reply

Steveie Aug. 22 at 2:21 PM

$ZVRA 5 years in the zvra, I'm glad I took most of my money and switched it to apld! Very happy! Did Neil resign yet??

2 · Reply

ChiefTanto Aug. 22 at 1:54 PM

$ZVRA I’m no SEC or M&A expert but Neil’s still holding ~27k shares of Travere and I’d imagine that creates conflict of interest that’d require him to recuse himself. Not that shady deals don’t happen all the time but this one would have some easily provable conflicts.

1 · Reply

EthanStawk Aug. 22 at 1:49 PM

$ZVRA Just out of curiosity, as I'm not an MBA... Isn't there a fiduciary duty to take the best offer or put all offers to the shareholders? They cannot just sell for say, $18, if they have larger corporations coming in at higher bids, right? In essence,vrye board doing what's best for the board and not us, which is how they roll.

1 · Reply

111ggg Aug. 22 at 1:35 PM

$ZVRA Kiss your rumor goodbye.

2 · Reply

ChiefTanto Aug. 22 at 1:33 PM

$ZVRA What is this 30c+ opening spread bullshit the past couple of days

0 · Reply

Market Cap	529.91M
Revenue (ttm)	23.61M
Net Income (ttm)	-105.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-446.89%
Debt to Equity Ratio	0.52

Volume	1,209,000
Avg Vol	1,325,318
Day's Range	N/A - N/A
Shares Out	56.14M
Stochastic %K	25%
Beta	1.87
Analysts	Strong Sell
Price Target	$23.71